canakinumab   Click here for help

GtoPdb Ligand ID: 6773

Synonyms: ACZ 885 | ACZ885 | Ilaris®
Approved drug Immunopharmacology Ligand
canakinumab is an approved drug (FDA (2009), EMA (2009))
Compound class: Antibody
Comment: Canakinumab targets interleukin-1β [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
No information available.
Summary of Clinical Use Click here for help
Used to treat rheumatic diseases; familial cold autoinflammatory syndrome (FCAS) [4] and Muckle-Wells syndrome (MWS) in patients >4 years of age, systemic juvenile idiopathic arthritis (sJIA) in patients >2 years old [7], and adult-onset Still's disease.

Unexpectedly, further analysis of data from the CANTOS cardiovascular disease trial revealed that IL-1β inhibition significantly reduced the incidence of hip and knee replacements compared to those not treated with canakinumab, suggesting application of canakinumab as a large joint osteoarthritis therapeutic [8].

SARS-CoV-2 and COVID-19: Canakinumab has been entered in to clinical trials that aim to determine its ability to combat the exaggerated immune response that drives cytokine storm and leads to tissue damage in the lung and other organs in patients with severe COVID-19.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
A monoclonal antibody which binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors [1], but it does not bind IL-1α or IL-1 receptor antagonist (IL-1ra). The patent claiming this antibody, US7446175, reports that the antigenic epitope on IL-1β is the loop containing the Glu64 residue in the mature cytokine (equivalent to residue 180 of the precursor peptide) [3]
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01327846 Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) Phase 3 Interventional Novartis Results from the CANTOS trial (NCT01327846) showed that canakinumab (in high-risk patients; in addition to standard-of-care therapy) reduced the number of recurrent cardiovascular events that were recorded at 3-4 years follow-up 2
NCT04365153 Canakinumab in Covid-19 Cardiac Injury (The Three C Study) Phase 2 Interventional The Cleveland Clinic
NCT04362813 Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia Phase 3 Interventional Novartis
External links Click here for help